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Background: Vascular thrombosis is a well-known complication after simultaneous pancreas-kidney (SPK) transplantation
procedures. The role of preoperative special coagulation studies to screen patients at high risk for vascular thrombosis is unclear
and not well studied.
Methods: This study reports a retrospective medical record review of 83 SPK procedures performed between April 2007 and
June 2013 in a single institution. All SPK transplantation recipients underwent preoperative screening for hypercoagulable state.
Results: Eighteen of 83 patients (21.69%) were diagnosed with vascular thrombosis of the pancreas. Of the 23 patients with at
least 1 positive screening test, only 4 had a thrombotic event (17.39%). On the other hand, 14 of 60 patients with negative
screening tests developed vascular thrombosis (23.33%). The hypercoagulable screening workup had a positive predictive value
of 17.39% and a negative predictive value of 76.67%. The workup also demonstrated low sensitivity (22.22%) and specificity
(70.77%).
Conclusion: No differences were seen in patient or graft survival between groups at 12 months. This retrospective study did not
show any benefit of using special coagulation studies to rule out patients at risk for vascular thrombosis after SPK
transplantation.
Keywords: Blood coagulation tests, kidney transplantation, mesenteric ischemia, organ transplantation, pancreas transplantation,
thrombosis
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INTRODUCTION
The first simultaneous pancreas-kidney (SPK) transplan-
tation was performed in 1966, and since then more than
2,200 SPK transplantations have been performed in the
United States.1 Vascular thrombosis is the major non-
immunologic cause of early pancreas allograft failure.2 The
incidence of pancreas allograft failure secondary to vascular
thrombosis is reported to be 4%-8% in SPK transplant
recipients and 10%-12% following solitary pancreas trans-
plantation.3 Indeed, the incidence of pancreas graft throm-
bosis in clinical pancreas transplantation has not changed
since the complication of vascular thrombosis was first
reported in the 11 pancreas transplantations done at the
University of Minnesota in the mid-1960s.4
Vascular thrombosis can occur early or late after
transplantation. Early thrombosis (within the first 2 weeks)
is usually multifactorial and related to donor and recipient
factors, preservation and procurement strategies, and
technical aspects of pancreas transplantation.5 Donor
factors such as increasing age, atherosclerosis, obesity,
cerebrovascular event as a cause of death, and the
presence of severe hypotension have all been cited as risk
factors for pancreas graft thrombosis.6 The type of
preservation solution and prolonged cold ischemia (>12-
14 hours) may also play a role. In recipients, severe vascular
disease, hypotension, orthostasis, and the presence of a
thrombophilic state, whether definitively diagnosed or
based on history, also increase the risk for thrombotic
events.6 Diabetes is associated with abnormalities or
defects in nearly all components of the coagulation system,
including platelets, vascular endothelium, coagulation fac-
tors, anticoagulants, and fibrinolysis.7-9 Beyond 2 weeks,
pancreas allograft thrombosis is usually mediated immunol-
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ogically and associated with acute rejection of the allo-
graft.10
Vascular thrombosis following SPK transplantation can be
either arterial or venous; however, venous thrombosis is a
more common event (2:1 ratio).11 Thrombosis may also be
subclassified as either complete or partial. Whereas
complete vascular occlusion generally results in graft loss,
partially occlusive thrombosis is associated with a higher
likelihood of pancreas graft survival.11,12 Because of the
segmental nature of pancreas arterial anatomy, thrombosis
of different arterial segments may lead to varying outcomes,
and in some cases, the collateral circulation within the
pancreas may prevent infarction. The occlusion of either the
splenic or superior mesenteric artery may result in partial
infarction of the graft. Likewise, different outcomes have
been observed for splenic venous thrombosis compared
with occlusion of the main portal vein in which graft loss is
nearly universal.10,12
The risk for vascular thrombosis depends on the type of
pancreas transplantation. Data from the Scientific Registry
of Transplant Recipients and the International Pancreas
Transplant Registry suggest that SPK transplant recipients
have less pancreas graft thrombosis compared with
pancreas after kidney or pancreas transplant alone recip-
ients.13 The anticoagulant effects of uremia and the lower
risk for acute rejection associated with SPK transplantation
are the most commonly cited reasons for this difference.13
Surgical techniques to manage exocrine secretions may
also be associated with variable risks for thrombosis. The
incidence of thrombosis is slightly higher in the setting of
enteric exocrine drainage compared with bladder drain-
age.13-15
We report our center’s experience of using pretransplan-
tation screening to diagnose a hypercoagulable condition in
SPK transplant recipients to identify patients at high risk for
vascular thrombosis.
METHODS
This study is a retrospective medical record review of
patients who underwent SPK transplantation between April
2007 and June 2013 in a single institution. The study was
approved by the institutional review board.
Routine preoperative screening for hypercoagulable
disorder included tests for prothombin time, activated partial
thromboplastin time, international normalized ratio, anti-
phospholipid antibodies (IgG and IgM), lupus anticoagulant,
protein C and protein S activity, factor V Leiden mutation,
prothrombin G20210A mutation, and antithrombin III level.
Diagnosis of thrombotic events was established by review-
ing imaging studies including Doppler ultrasounds and
computed tomography angiograms. We also reviewed
inpatient hospital notes, discharge summaries, and outpa-
tient clinic visits.
Organs were placed intraperitoneally with pancreas
exocrine drainage to a jejunal loop without Roux-en-Y and
venous drainage into the portal circulation. All patients had
routine Doppler ultrasound of the pancreas and kidney
allograft at days 1 and 7 post-SPK and whenever clinically
indicated.
All patients received induction immunosuppression with
antithymocyte globulin (rabbit antithymocyte globulin, 1.5
mg/kg 3 3 doses). Maintenance immunosuppression
consisted of tacrolimus, mycophenolate mofetil (MMF),
and steroids. Tacrolimus troughs were maintained at 10-
15 ng/mL during the first 3 months and 10-12 ng/mL until
the end of the first year. MMF dose was maintained at 1,000
mg twice daily, and prednisone was tapered to 5 mg 3-6
months after the surgery.
At our center, we administer 325 mg of enteric-coated
aspirin to all SPK transplant recipients. Patients with positive
screening tests and/or history of thrombophilic disorders
are usually referred to hematology for detailed evaluation.
We have used anticoagulation on a case-by-case basis;
however, no strict protocol exists regarding perioperative
care of patients with a positive screening test. The duration
of treatment depends on the clinical history of thrombophilia
and the perceived risk of thrombosis as ascertained by the
hematologist.
We reported partial and complete thrombosis involving
either a pancreas or kidney allograft including the pancre-
atic conduit artery, superior mesenteric artery, splenic
artery, portal vein, renal artery, renal vein, and/or iliac
vessels. We also looked at transplantation kidney biopsy
reports and the incidence of renal and pancreas allograft
loss.
Demographic variables included age, sex, race, body
mass index (BMI), and type of diabetes (type 1 vs type 2).
For numeric variables (age and BMI), mean and standard
deviation are reported. For categorical variables, occur-
rence and percentage are reported. Two-sample t test was
employed for continuous variables such as age and BMI,
and Fisher exact test was employed for categorical
variables: sex, type of diabetes, and race. We calculated
sensitivity, specificity, positive predictive value, and negative
predictive value using standard methods. P value <0.05
was considered statistically significant.
RESULTS
Ninety-six patients received SPK transplantation at our
center between April 2007 and June 2013. All of the patients
were dialysis dependent at the time of surgery. Of them, 13
patients were excluded because of incomplete data, and 83
patients were included for final analysis (Table 1). Eighteen
of 83 (21.69%) patients were diagnosed with a thrombotic
event, whereas 65 of 83 (78.31%) remained free of
thrombotic complications. No statistical difference between
the 2 groups was seen in age, sex, and BMI. An increased
trend of vascular thrombosis in type 1 diabetics (66.67% vs
49.23%) and Caucasians (61.11% vs 46.15%) was noted;
however, the P values were not significant.
The figure is a schematic illustration of the study design.
Of the 83 patients whose data were available for final
analysis, 23 (27.71%) patients had at least 1 positive
screening test. One patient had 3 positive screening tests,
and 2 patients had 2 positive screening tests each. Among
the 23 patients with at least 1 positive screening test, only 4
(17.39%) had a thrombotic event, while 14 of 60 (23.33%)
patients with negative screening tests were diagnosed with
vascular thrombosis. Twelve of the 18 patients with a
thrombotic event presented with venous thrombosis involv-
ing the splenic vein, portal vein, or both. Most of the
vascular thromboses were partial and nonocclusive (Table
2).
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The screening workup had a positive predictive value of
17.39% and a negative predictive value of 76.67%.
Sensitivity of the screening panel to rule out a thrombotic
event after SPK transplantation was 22.22%, and specificity
was 70.77% (Table 3).
Six pancreas allografts failed during the study period
(data not shown). Four of the 6 graft losses occurred in
patients with vascular thrombosis; however, no difference in
graft and patient survival was seen at 12 months between
the 2 groups.
DISCUSSION
Pancreas graft thrombosis remains one of the most
common reasons for pancreas allograft loss. Thrombecto-
my may salvage the pancreas graft if performed early;
however, pancreas graft loss is the most commonly
observed scenario in cases with total venous or arterial
occlusion.16,17 In addition to graft loss, vascular thrombosis
leads to prolonged hospital stay and increased readmission
rates and contributes to increased patient morbidity.17,18
Patients undergoing SPK transplantation may have all the
risk factors associated with formation of a thrombus. Their
blood flow may be low because of low venous pressure
system, microvascular disease, and perioperative hypoten-
sion. If the vascular endothelium is injured because of
ischemia-reperfusion injury, the patient may be more
susceptible to thrombosis. Last, thrombophilia and hyper-
coagulable states are prevalent in patients with diabe-
tes.19,20
Most transplantation centers in the United States admin-
ister some form of anticoagulation following SPK transplan-
tation. Low-dose aspirin is generally recommended for all
pancreas recipients, although no literature supports its use.
Unfractionated heparin or low molecular weight heparin
(LMWH; enoxaparin) may also be used to reduce the risk of
vascular thrombosis after pancreas transplantation, al-
though the risk of perioperative bleeding remains signifi-
cant.21,22 The dose of LMWH needs to be adjusted in
patients with renal insufficiency, and the change in renal
function following SPK transplantation makes the dosing of
LMWH problematic.23-25 Warfarin is typically not recom-
mended in the immediate posttransplantation period;
however, it is frequently used as a long-term anticoagulant
for prophylaxis of vascular thrombosis in patients with
thrombophilic disorders.
Surprisingly, risk stratification for thrombotic complica-
tions after SPK transplantation has not been given much
attention. To the best of our knowledge, the role of
screening tests to rule out a hypercoagulable disorder has
not been studied in this population of patients, and our
study is the first to address this question. It is pertinent to
evaluate transplant candidates with thrombophilia and
identify patients at highest risk for thrombotic complications.
However, such an extensive preoperative workup repre-
sents a significant financial burden for the institution and
increases the cost of the pretransplantation evaluation. In
the absence of data supporting the use of pretransplanta-
tion screening for a hypercoagulable disorder, we consid-
ered it important to look at the incidence of vascular
thrombosis and graft failure in this population.
Our study failed to show any demonstrable effect of using
screening tests to predict a thrombotic event after SPK
transplantation. Sensitivity of the testing panel was poor
because we only correctly identified 22.22% of event-
positive patients with a high false-negative rate (77.78%,
type II error). The testing panel performed slightly better in
excluding a thrombotic event (specificity 70.77%); however,
the false-positive rate was 29.23% (type I error).
Table 1. Baseline Demographics of Patients with
Simultaneous Pancreas-Kidney Transplantation (n¼83)
Variable
Thrombotic
Event n¼18
No Thrombotic
Event n¼65 P Value
Mean age,
years (SD) 41.39 (10.43) 42.04 (9.03) 0.8547
Sex, n (%) 0.7686
Male 14 (77.78) 47 (72.31)
Female 4 (22.22) 18 (27.69)
Type of diabetes
mellitus, n (%) 0.2860
Type 1 12 (66.67) 32 (49.23)
Type 2 6 (33.33) 33 (50.77)
Race, n (%) 0.4258
Caucasian 11 (61.11) 30 (46.15)
African American 7 (38.89) 32 (49.23)
Other 0 (0.00) 3 (4.62)
Mean BMI,
kg/m2 (SD) 25.46 (3.91) 27.36 (4.95) 0.1483
BMI, body mass index.
Figure. Schematic illustration of the study.
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In our study, the hypercoagulable screening testing had a
low positive predictive value of 17.39%, meaning that only
17.39% of the patients with ‡1 positive screening tests
developed vascular thrombus. This result may be because
of the relatively low prevalence of vascular thrombosis in
this population. Negative predictive value on the screening
panel performed better in that 76.67% of the patients with
negative screening test results remained event-free; how-
ever, negative predictive value is not sufficiently reliable to
be used as a screening tool.
Based on our results, we do not recommend a pretrans-
plantation hypercoagulable screening workup because of
the low yield and unfavorable cost-benefit ratio. The use of
anticoagulation in the perioperative period should be
individualized and based on each center’s experience.
High-risk populations, such as patients with a history of
thrombophilic disorders, multiple abortions, systemic lupus
erythematosus, or multiple clotted accesses, may be
screened prior to SPK transplantation. In the early post-
transplantation period, a high index of suspicion and the
routine use of Doppler ultrasound to evaluate pancreas
perfusion are also highly recommended.
We recognize the limitations of our retrospective study
without a control group. Also, factors such as ischemia-
reperfusion injury, cold ischemia time, and postoperative
hypotension, which could potentially cause vascular throm-
bosis, could not be taken into account because of the
retrospective nature of the study. The positive predictive
value and negative predictive value of the testing may also
be skewed because of the relatively low prevalence of
vascular thrombosis in patients with SPK transplantations.
CONCLUSION
In conclusion, our study showed no benefit of pretrans-
plantation screening for vascular thrombosis with special
coagulation studies in patients undergoing SPK transplan-
tation. The decision to screen and administer anticoagu-
lants to potential SPK transplantation recipients should be
made on clinical grounds.
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